Scarica l'app Stockscreener
0.5783
3.27%
0.0183
Dopo l'orario di chiusura:
.58
0.0017
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Veru Inc Borsa (VERU) Ultime notizie
Veru Inc (VERU) Shares Down Despite Recent Market Volatility - The News Heater
Veru Inc (VERU Stock: A Sea of Opportunity - The InvestChronicle
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Veru (VERU) Projected to Post Earnings on Thursday - MarketBeat
Veru Inc (VERU) is looking forward to a strong quarter - SETE News
What will the future hold for Veru Inc (NASDAQ:VERU) stock? - US Post News
Veru (VERU) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Oppenheimer maintains Veru stock Outperform rating, $5 target - MSN
Veru (VERU) to Release Quarterly Earnings on Thursday - Defense World
Veru shares plunge despite positive data in obesity trial - pharmaphorum
Oppenheimer maintains Veru stock Outperform rating, $5 target By Investing.com - Investing.com Australia
Veru Hopes To Improve The QUALITY Of Drug-Induced Weight Loss - Citeline
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Benzinga
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough? - BioSpace
Muscle-building drug improves body composition in obesity trial, Veru says - BioPharma Dive
Dow Edges Higher; AT&T Posts Upbeat Earnings - Benzinga
Veru's experimental drug helps older obese patients on Wegovy preserve muscle - Reuters
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough - Benzinga
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Benzinga
Veru down 46% despite data for drug preserving lean body mass in Wegovy users - Seeking Alpha
Veru Reports Positive Data From Phase 2b QUALITY Study - Nasdaq
Veru’s enobosarm meets primary endpoint in Phase 2b weight reduction trial - TipRanks
Veru says its drug preserved lean mass in patients taking Wegovy - STAT
Veru Announces Positive Topline Data from Phase 2b QUALITY - GlobeNewswire
Veru's Enobosarm + Wegovy Trial Shows 71% Better Muscle Preservation in Weight Loss Study - StockTitan
Oppenheimer maintains Veru stock Outperform rating as trial nears - MSN
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN
Novo weight-loss data roll out; Veru ‘leans’ in - BioWorld Online
Oppenheimer maintains Veru stock Outperform rating as trial nears By Investing.com - Investing.com Canada
Items Tagged with 'enobosarm' - BioWorld Online
Investors Purchase High Volume of Veru Call Options (NASDAQ:VERU) - Defense World
Veru Target of Unusually High Options Trading (NASDAQ:VERU) - MarketBeat
Investors Buy Large Volume of Veru Call Options (NASDAQ:VERU) - MarketBeat
Jane Street Group LLC Has $74,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
Will QUALITY Add More Weight To Veru Stock? - RTTNews
What is B. Riley's Forecast for Veru Q1 Earnings? - MarketBeat
What is B. Riley’s Forecast for Veru Q1 Earnings? - Defense World
Veru Inc. (NASDAQ:VERU) Shares Purchased by Geode Capital Management LLC - Defense World
Barclays PLC Has $142,000 Stock Holdings in Veru Inc. (NASDAQ:VERU) - Defense World
H.C. Wainwright maintains target on Veru stock post-sale By Investing.com - Investing.com Nigeria
Veru Inc. Sells FC2 Business to Focus on Biopharma - TipRanks
Veru (NASDAQ:VERU) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright maintains target on Veru stock post-sale - Investing.com India
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Veru's (VERU) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Veru Inc. (NASDAQ:VERU) Shares Bought by State Street Corp - Defense World
Biopharma company to cut 90% of jobs after sale - The Business Journals
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):